8 minute read
Jun. 3, 2024
Cerevance’s CNS-Penetrant KCNK13 Inhibitor Targets Brain-Specific NLRP3-Inflammasome Blockade
CVN293
oral, CNS-penetrant, selective inhibitor of KCNK13 Ph. I in healthy subjects HTS following NETSseq identification of target ACS Med. Chem. Lett., March 2024 Cerevance, Cambridge, UK
Loading...
